Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in oncology resources.
Related to this article
The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 trial, with a PDUFA date of June 25, 2027.
Advertisement
Advertisement
Trending on Targeted Onc
1
Home-Based Trastuzumab Self-Administration Reduces Costs and Time Burden
2
Comparing Treatment Approaches in Second-Line Metastatic ccRCC
3
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
4
Denileukin Diftitox Improves QOL in Responding Patients With CTCL
5